GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Total Inventories

YMAB (Y-mAbs Therapeutics) Total Inventories : $9.56 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Total Inventories?

Y-mAbs Therapeutics's total inventories for the quarter that ended in Sep. 2024 was $9.56 Mil. Y-mAbs Therapeutics's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $9.03 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Y-mAbs Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $1.33.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Y-mAbs Therapeutics's Days Inventory for the three months ended in Sep. 2024 was 366.44.

Inventory Turnover measures how fast the company turns over its inventory within a year. Y-mAbs Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.25.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Y-mAbs Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.49.


Y-mAbs Therapeutics Total Inventories Historical Data

The historical data trend for Y-mAbs Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Total Inventories Chart

Y-mAbs Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial - - 5.51 6.70 5.07

Y-mAbs Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.11 5.07 8.45 8.50 9.56

Y-mAbs Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Y-mAbs Therapeutics  (NAS:YMAB) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Y-mAbs Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

Net-Net Working Capital Per Share (Q: Sep. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(68.122+0.75 * 19.916+0.5 * 9.557-28.488
-0-0)/44.7668
=1.33

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Y-mAbs Therapeutics's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2024 )/Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=9.0275/2.248*365 / 4
=366.44

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Y-mAbs Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2024 ) / Average Total Inventories (Q: Sep. 2024 )
=2.248 / 9.0275
=0.25

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Y-mAbs Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=9.0275 / 18.461
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Y-mAbs Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-mAbs Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
230 Park Avenue, Suite 3350, New York, NY, USA, 10169
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Executives
Thomas Gad director, officer: President and Chairman C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Torben Lund-hansen officer: Sr. VP and Head of Tech Op C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Joris Wilms officer: Sr. VP and COO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Bo Kruse director, officer: EVP, CFO, Secy & Treas. C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Susan Laura Smith officer: Senior Vice President, CCO 5 OVERLOOK CT, LAMBERTVILLE NJ 08530
Vignesh Rajah officer: SVP and CMO HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Johan Wedell-wedellsborg director, 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Biotech Aps Wg 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Michael J Rossi director, officer: President & CEO 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus director, officer: Chief Executive Officer C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed officer: Sr. VP and CSO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman officer: Sr. VP and CCO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169